Opinion

Video

Advancing Treatment for EGFR-Mutant Advanced NSCLC: Lessons from FLAURA2

Helena A. Yu, MD, discusses her treatment strategy for patients with EGFR-mutant non-small cell lung cancer (NSCLC), emphasizing current guidelines and standard of care, while Zosia Piotrowska, MD, MHS, examines the key efficacy and safety findings from the FLAURA2 study, which evaluated first-line osimertinib combined with chemotherapy in patients with advanced EGFR-mutant NSCLC.

  1. Briefly discuss your general treatment approach in patients with EGFR-mutant NSCLC.
    • What treatment options are available? What is the standard of care in this setting?
    • What factors do you consider in guiding treatment selection?
  2. Please review key efficacy and safety data from FLAURA2 evaluating 1L osimertinib with chemotherapy in patients with EGFR-mutant advanced NSCLC.(Janne, et al. WCLC 2023. Abstract PL03.13; Planchard, et al. ESMO 2023. Abstract LBA68)
    • What implications may these findings have on clinical practice?
Related Videos
5 KOLs are featured in this panel.
5 KOLs are featured in this panel.
2 KOLs are featured in this panel.
2 KOLs are featured in this panel.
Video 6 - 2 KOLs are featured in, "Other trials of note investigating targeted therapies in later line HR+/HER2- mBC"
Video 5 - 2 KOLs are featured in, "Targeted Therapies in HR+/HER2- mBC: CAPItello-291"
4 KOLs are featured in this series
4 KOLs are featured in this series
2 KOLs are featured in this program.
2 KOLs are featured in this program.